Clinical Benefit Response in Pancreatic Cancer Trials Revisited

Publisher： Karger

E-ISSN： 2296-5262|37|1-2|42-48

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.37, Iss.1-2, 2014-01, pp. : 42-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1728-1730

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-05 ,pp. : 357-362

Karger

Access to resources Recommend Favorite

Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 3, 2009-01 ,pp. : 151-156

Karger

Access to resources Recommend Favorite

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

By Jordheim Lars Petter   Dumontet Charles  

Biomarkers in Medicine, Vol. 7, Iss. 4, 2013-08 ,pp. : 663-671

Future Medicine

Access to resources Recommend Favorite

Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials

By  

Oncology, Vol. 81, Iss. 3-4, 2011-10 ,pp. : 143-150

Karger

Access to resources Recommend Favorite